Researchbreadcrumb separatorStudiesbreadcrumb separatorD:A:Dbreadcrumb separatorPresentationsbreadcrumb separator2014
Presentations 2014

HIV Drug Therapy Glasgow 2014, 2nd-6th November 2014

Oral presentations 

O322: A clinically useful risk-score for chronic kidney disease (CKD) in HIV infection
Presented by Amanda Mocroft posteroral presentation

O315: Lack of Association between Use of  Efavirenz and Death from Suicide: D:A:D Study Presented by C. Smith posteroral presentation

O324: Gender Differences in the Use of Cardiovascular Disease-related Interventions Among HIV-Positive persons: D:A:D Study Presented by Camilla Ingrid Hatleberg poster, oral presentation

20th International AIDS conference, Melbourne Australia, 20th - 25th 2014

 Impact of short-term change in body mass index after antiretroviral therapy initiation on subsequent risk of cardiovascular disease and diabetes in HIV-positive individuals: the D:A:D study. A Achhra et al. Presentation

21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston


Association Between Dideoxynucleoside Analogues (d-drugs) and End-Stage Liver Disease (ESLD)
Presented by Lene Ryom on behalf of DAD

Predictors of Progression, Stabilisation or Improvement of eGFR After Chronic Renal Impairment Presented by Lene Ryom on behalf of D:A:D

Is there continued evidence for an association between abacavir and myocardial infarction risk? Presented by Caroline Sabin on behalf of D:A:D